Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02248805 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
A Phase 1 study of Colorectal Carcinoma, sponsored by MacroGenics.
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
- 8
- Study locations
NCT02248805 is a Phase 1 study of Colorectal Carcinoma that has completed, run by MacroGenics. The registered enrollment target is 95 participants, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (91% lower). The trial reports 8 study locations across 6 states.
The verdict
NCT02248805, a Phase 1 study of Colorectal Carcinoma, has completed, sponsored by MacroGenics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
- 8
- Study locations
Study Summary
The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD007 will also be assessed.
Conditions Studied
Interventions
- DRUG MGD007
Study Locations (8)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
North Carolina
- Duke University Medical Center - Durham
- Carolina Biooncology Institute - Huntersville
Connecticut
- Yale University, Yale Cancer Center - New Haven
Florida
- H. Lee Moffitt Cancer Center & Research Institute, Inc - Tampa
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
Oregon
- Providence Portland Medical Center - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-10 |
| Est. Completion | 2018-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02248805
The ClinicalTrials.gov registry entry for NCT02248805 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,095-participant average among 53 other Colorectal Carcinoma trials with a reported enrollment target (91% lower). The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which MGD007 is the first listed.
NCT02248805 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Massachusetts, North Carolina, Connecticut.
Frequently Asked Questions
What is clinical trial NCT02248805 about?
NCT02248805 is a clinical study titled "Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma". The primary goal of this Phase 1 study is to characterize the safety and tolerability of MGD007 and establish the maximum tolerated dose (MTD) and schedule of MGD007 administered to patients with metastatic colorectal carcinoma. Pharmacokinetics, pharmacodynamics, and the anti-tumor activity of MGD0...
What is the current status of trial NCT02248805?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2014-10. Estimated completion is 2018-07-02.
What conditions does trial NCT02248805 study?
This clinical trial studies the following conditions: Colorectal Carcinoma.
What interventions are being tested in trial NCT02248805?
The interventions under investigation include: MGD007 (DRUG).
Who is sponsoring clinical trial NCT02248805?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02248805 being conducted?
This trial has 8 study locations across Connecticut, Florida, Maryland, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
RECRUITING · Phase 1
-
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Test Different Doses of BI 765049 in People With Advanced Cancer of the Colon, Rectum, Stomach, or Pancreas
RECRUITING · Phase 1
-
Testing for Safety and Colorectal Cancer Preventive Effects of ONC201
RECRUITING · Phase 1
-
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.